Hui R, Özgüroğlu M, Daniel D, et al. Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract PL 02.02.
(Neo)adjuvant erlotinib plus cisplatine verbetert uitkomsten bij stadium III NSCLC
okt 2018 | Longoncologie